Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

22.83 +0.23 (+1.02%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
From Uncertainty to Strength: Navigating Life with Cervical Cancer
(BPT) - Sponsored by Pfizer Inc. and Genmab A/S 
Via Brandpoint
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Pfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 Outlook
The company also reiterated its outlook for 2024. 
Via Investor's Business Daily
Is Pfizer a Millionaire Maker?
Via The Motley Fool
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy
Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS. 
Via Investor's Business Daily
3 of the Safest Ultra-High-Yield Dividend Stocks to Buy in 2025
These top-tier income stocks are sporting an average yield of 8.53%! 
Via The Motley Fool
What's Going On With CVS Health, UnitedHealth And Cigna Group Shares?
Shares of Pharmacy-benefit managers (PBMs) including CVS Health Corp (NYSE:CVS), UnitedHealth Group Inc (NYSE:UNH) and Cigna Group (NYSE:CI) are moving lower Tuesday on continued downside pressure... 
Via Benzinga
Topics Government
Exposures Political
Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance Breaks
Shares of Pfizer (PFE) are trading higher after the company affirmed its guidance. They are currently testing resistance. 
Via Benzinga
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
Wall Street began Tuesday’s session on a weaker note, with major indices slipping after November's robust retail sales report reignited investor concerns that the Federal Reserve might hold back... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025
Pfizer projects 2025 revenues of $61-$64 billion, adjusted EPS of $2.80-$3.00, and $24-$26 billion in combined SI&A and R&D expenses while reaffirming its 2024 guidance. 
Via Benzinga
Pfizer Stock Jumps After 2025 Revenue Outlook Offsets $1B Hit From Inflation Reduction Act Changes: Retail’s More Bullish
Pfizer said the projection reflects stable revenue from COVID-19 products, excluding approximately $1.2 billion of non-recurring revenue for Paxlovid in 2024. 
Via Stocktwits
Topics Economy
Exposures COVID-19 Interest Rates
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025. 
Via Investor's Business Daily
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
From Pfizer Inc.
Via Business Wire
Prediction: 2 Stocks That'll Be Worth More Than Palantir 5 Years From Now
Via The Motley Fool
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
Pfizer's 2025 guidance to be revealed Tuesday. Goldman Sachs predicts $64.9 billion revenue and EPS of $3.13, supported by Paxlovid and Eliquis growth. 
Via Benzinga
Expecting? How getting vaccinated while pregnant can help protect newborns from RSV
(BPT) - Expecting mothers have countless preparations to make before their little ones arrive, from decorating the nursery and installing a car seat to picking a pediatrician and thinking about... 
Via Brandpoint
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
Via The Motley Fool
Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children
Lawyer files petition against polio vaccine, part of broader anti-vaccine campaign by Robert F. Kennedy Jr. and Aaron Siri, causing concerns for vaccine policies and pharma companies. Trump considering... 
Via Benzinga
Topics Government
Exposures Political Product Safety
Setting Goals: How to manage a chronic inflammatory disease
(BPT) - Content sponsored and provided by Pfizer. Ashley partnered with Pfizer to share her experience living with moderate to severe rheumatoid arthritis (RA). 
Via Brandpoint
Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination
Avian flu continues to spread with cases in cats, horses, and humans. Scientists monitor wildlife infections. Vaccine development may face challenges. 
Via Benzinga
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
Pfizer Declares First-Quarter 2025 Dividend
From Pfizer Inc
Via Business Wire
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027. 
Via Benzinga
Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a favorable safety profile. 
Via Benzinga
Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
From Pfizer Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.